Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:The efficacy, safety and tolerability of canakinumab in the treatment of familial Mediterranean fever : a systematic review of the literature
Authors:Kačar, Mark (Author)
Savic, Sinisa (Author)
van der Hilst, Jeroen CH (Author)
Language:English
Tipology:1.02 - Review Article
Organisation:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Familial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%-10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchicine in doses needed to prevent attacks. For these patients, Canakinumab, a full human antibody against IL-1[beta], has been approved recently by the FDA and EMA. In this article, we present a systematic review of the long-term efficacy, safety, and tolerability of Canakinumab in FMF patients who cannot tolerate colchicine or who are resistant to colchicine treatment.
Keywords:familial Mediterranean fever -- therapy -- review, monoclonal antibodies, canakinumab, anti-IL1 therapy
Year of publishing:2020
Publisher:Dove Press
Source:Nova Zelandija
COBISS_ID:58075139 Link is opened in a new window
UDC:577.2
ISSN on article:1178-7031
DOI:10.2147/JIR.S206204 Link is opened in a new window
Note:Nasl. z nasl. zaslona; Opis vira z dne 1. 4. 2021;
Views:698
Downloads:341
Files:.pdf PDF - Presentation file, download (463,72 KB)
URL URL - Source URL, visit https://www.dovepress.com/getfile.php?fileID=56642
 
Journal:J. inflamm. res.
Dove Medical Press
 
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Rights:© 2020 Kacar et al.
:
  
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


Licences

License:CC BY-NC 3.0, Creative Commons Attribution Non-Commercial 3.0
Link:http://creativecommons.org/licenses/by-nc/3.0/
Description:You are free to reproduce and redistribute the material in any medium or format. You are free to remix, transform, and build upon the material. You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Licensing start date:20.02.2020

Back